Artesunate ameliorates acute pancreatitis by enhancing p62-mediated zymophagy through non-canonical NRF2 activation.
- 1Department of Pharmacology, College of Pharmacy, Army Medical University, Chongqing 400038, China.
- 2Biomedical Analysis Center, Army Medical University, Chongqing 400038, China.
- 3Department of Pharmaceutical Analysis, College of Pharmacy, Army Medical University, Chongqing 400038, China.
Abstract
Zymophagy is a selective autophagy that eliminates activated trypsinogen during acute pancreatitis (AP). However, the upstream regulatory mechanisms and therapeutic potential of zymophagy remain poorly understood. This study investigated the mechanisms of zymophagy activation and its protective role in AP, using artesunate (AS) as a pharmacological tool. AP models were induced by cerulein combined with lipopolysaccharide and evaluated by histopathological examination and enzymatic assays. Gene expression was knocked down with specific shRNA or siRNA, and expression levels were detected by real-time polymerase chain reaction (PCR). Zymophagy and its regulatory mechanisms were characterized through multiple experiments, and molecular interactions were validated by co-localization, immunoprecipitation (IP), chromatin immunoprecipitation (ChIP), thermal shift assay, and molecular docking. AS mitigated AP in both in vivo and in vitro models by inhibiting trypsinogen hyperactivation in acinar cells. This protective effect was mediated by enhanced Atg5-mediated zymophagy activation via a p62-dependent and vacuole membrane protein 1 (VMP1)-ubiquitin-involved pathway, which promotes the targeted engulfment and degradation of trypsinogen. Mechanistically, AS binds the PB1 domain of p62, strengthens its interaction with Kelch-like ECH-associated protein 1 (Keap1), triggers ubiquitin-p62-mediated autophagic degradation of Keap1, facilitates the nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2) and its selective binding to the antioxidant response element in the p62 promoter, and ultimately upregulates p62 transcription. Zymophagy is activated via a VMP1-ubiquitin-p62-dependent and Atg5-mediated canonical autophagy pathway. AS ameliorates AP by enhancing p62-mediated zymophagy via non-canonical NRF2 activation, which provides mechanistic evidence for therapeutic targeting of acinar zymophagy in AP management.
Related
- Gut microbiota-derived phenylalanine metabolites exacerbate elderly-onset acute pancreatitis by promoting mitophagy and enhancing cell death
- N-Acetylglucosamine ameliorates knee osteoarthritis by enhancing UDP-GlcNAc conversion and chondrocyte DNA repair capacity
- Pharmacological Activation of Autophagy Ameliorates Neuromuscular-Associated Defects and Extends Lifespan in a Caenorhabditis elegans Model of Spinal Muscular Atrophy.
- Paeoniflorin ameliorates Parkinson’s disease by promoting autophagy to inhibit A1 phenotype astrocyte activation
- 4-Octyl itaconate ameliorates cigarette smoke-induced chronic obstructive pulmonary disease by suppressing necroptosis in alveolar macrophages via Nrf2 activation
BibTeX
@article{cen2026artesunate,
title = {{Artesunate ameliorates acute pancreatitis by enhancing p62-mediated zymophagy through non-canonical NRF2 activation.}},
author = {Yanyan Cen and Yalan Xiong and Chenxu Liu and Pan Wang and Ting Zhu and Fei Li and Haigang Zhang and Wenxuan Cao and Youcai Deng and Xichun Pan},
journal = {Precision clinical medicine},
year = {2026},
month = oct,
doi = {10.1093/pcmedi/pbag029},
url = {https://europepmc.org/article/MED/42953221},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Artesunate ameliorates acute pancreatitis by enhancing p62-mediated zymophagy through non-canonical NRF2 activation.
AU - Yanyan Cen
AU - Yalan Xiong
AU - Chenxu Liu
AU - Pan Wang
AU - Ting Zhu
AU - Fei Li
AU - Haigang Zhang
AU - Wenxuan Cao
AU - Youcai Deng
AU - Xichun Pan
PY - 2026
DA - 2026/10/13
JO - Precision clinical medicine
DO - 10.1093/pcmedi/pbag029
UR - https://europepmc.org/article/MED/42953221
AB - Zymophagy is a selective autophagy that eliminates activated trypsinogen during acute pancreatitis (AP). However, the upstream regulatory mechanisms and therapeutic potential of zymophagy remain poorly understood. This study investigated the mechanisms of zymophagy activation and its protective role in AP, using artesunate (AS) as a pharmacological tool. AP models were induced by cerulein combined with lipopolysaccharide and evaluated by histopathological examination and enzymatic assays. Gene expression was knocked down with specific shRNA or siRNA, and expression levels were detected by real-time polymerase chain reaction (PCR). Zymophagy and its regulatory mechanisms were characterized through multiple experiments, and molecular interactions were validated by co-localization, immunoprecipitation (IP), chromatin immunoprecipitation (ChIP), thermal shift assay, and molecular docking. AS mitigated AP in both in vivo and in vitro models by inhibiting trypsinogen hyperactivation in acinar cells. This protective effect was mediated by enhanced Atg5-mediated zymophagy activation via a p62-dependent and vacuole membrane protein 1 (VMP1)-ubiquitin-involved pathway, which promotes the targeted engulfment and degradation of trypsinogen. Mechanistically, AS binds the PB1 domain of p62, strengthens its interaction with Kelch-like ECH-associated protein 1 (Keap1), triggers ubiquitin-p62-mediated autophagic degradation of Keap1, facilitates the nuclear translocation of nuclear factor erythroid 2-related factor 2 (NRF2) and its selective binding to the antioxidant response element in the p62 promoter, and ultimately upregulates p62 transcription. Zymophagy is activated via a VMP1-ubiquitin-p62-dependent and Atg5-mediated canonical autophagy pathway. AS ameliorates AP by enhancing p62-mediated zymophagy via non-canonical NRF2 activation, which provides mechanistic evidence for therapeutic targeting of acinar zymophagy in AP management.
SN - 2096-5303
SN - 2516-1571
ER -